Company*
(Symbol)**

Funding Institution

Amount (M)

Type

Details (Date)

Adenosine Therapeutics LLC*

National Institute of Neurological Disorders and Stroke

$0.137

Fast-track SBIR grant

To fund additional research on the company's selective A2A adenosine receptor agonist, ATL-146e, for the prevention of injury due to spinal cord ischemia (3/11)

Adenosine Therapeutics LLC*

National Institute of Allergy and Infectious Diseases

$1.04

Phase II SBTTR grant

To continue development of A2A adenosine receptor agonists as an adjunct therapy for sepsis and sepsis syndrome (5/30)

Affinium Pharmaceuticals* (Canada)

Genome Canada and the Ontario Genomics Institute

$7

Research grant

For a program in viral proteomics (4/8)

Altea Development Corp.*

National Institute of Diabetes and Digestive and Kidney Diseases

$0.944

Phase II SBIR grant

To continue studies with Altea's MicroPor system for the non- invasive delivery of insulin (1/22)

Anadys Pharmaceuticals Inc.*

National Institutes of Health

$0.225

Phase I SBIR grant

For work on identifying novel antibiotics using structure-assisted drug design to discover and optimize small molecules that bind to and disrupt the function of the bacterial ribosome (2/25)

Antigen Express Inc.*

National Cancer Institute

$0.292

Phase I SBIR grant

To extend the development of a MHC Class II-based intratumoral gene therapy to produce an in vivo therapeutic cancer vaccine that elicits a helper T-cell anticancer response (4/29)

Antigen Express Inc.*

National Institute of Allergy and Infectious Diseases

$0.3

Phase I SBIR grant

To develop an Ii-key MHC Class II epitope-based vaccine to treat HIV (6/3)

Aphios Corp.*

National Cancer Institute

ND

Phase I SBIR grant

To develop a natural pharmaceutical-grade (delta)9-THC product for medical use (6/4)

Atox Bio* (Israel)

U.S. Department of Defense

$3.1

Research grant

To develop and commercialize treatment that would prevent the deadly sequelae of toxic shock caused by Staphylococcal and Streptococcal bacteria, potential bioweapons (5/8***)

Avanir Pharmaceuticals Inc. (AMEX:AVN)

California Trade, Technology and Commerce Agency

$0.15

California Technology Investment Partnership grant

For defining and assessing the market for a genital herpes product using docosanol 10% cream (5/2)

Avanir Pharmaceuticals Inc. (AMEX:AVN)

National Institutes of Health

$1

Phase II SBIR grant

To develop a docosanol-based product as a topical treatment for reducing the severity and healing time of recurrent genital herpes infections (3/20)

Biotica Technology Ltd. (UK)

European Union

€0.33 (US$0.29)

Marie Curie Industry Host Fellowship grant

To fund research for the design of polyketides for use as therapeutic substances and the development of new technologies for their production within micro-organisms (1/8)

Biotica Technology Ltd.* (UK)

Biotechnology and Biological Sciences Research Council

$0.286

Small Business Research Initiative grant

To fund research into new technologies that generate polyketides and peptides, and for their production within micro-organisms (4/8)

Boston Biomedica Inc. (BBII)

National Institutes of Health

$0.7

Phase II SBIR grant

For the use of its Pressure Cycling Technology to release DNA, RNA and proteins from cells and tissues, with particular emphasis on hard-to-lyse biomaterials (3/14)

Cognia Corp.*

National Institutes for General Medical Sciences

$1

Phase II SBIR grant

To further develop Cognia's protein database system, which is a curation and relational database system with graphic user interfaces that provide researchers with network and pathway builder tools, as well as advanced search algorithms (6/12)

CombiMatrix Corp. (subsidiary of Acacia Research Corp.; ACRI)

National Institutes of Health

ND

Phase I grant

For the development of its protein biochip technology (2/20)

Compugen Ltd. (Israel; CGEN) and DiagnoCure Inc. (Canada; TSE:CUR)

Canada-Israel Industrial Research and Development Foundation

C$0.8 (US$0.5)

Grant

To assist in the research and development of a nucleic acid probe-based diagnostic kit for the early detection of lung cancer (3/13)

Consensus Pharmaceuticals Inc.*

National Institute of Allergy and Infectious Diseases

ND

Phase I SBIR grant

To advance its drug discovery program for CD4 receptor antagonists to prevent HIV from entering cells (4/16)

Copernicus Therapeutics Inc.*

Cystic Fibrosis Foundation

$0.937

Development grant

To advance the development of therapeutic treatments for cystic fibrosis (3/12)

Copernicus Therapeutics Inc.*

State of Ohio

ND

Technology Action Fund grant

To fund optimization of aerosols of its nonviral compacted DNA nanoparticles for intrapulmonary delivery (6/20)

CytoGenix Inc.*

National Institutes of Health

ND

Phase I SBTTR grant

To test the company's single-stranded DNA expression systems in a transgenic mouse model (3/26)

Elitra Pharmaceuticals Inc.*

Genome Canada and Genome Quebec

C$5.74 (US$3.5)

Research grant

For Elitra's functional genomics efforts in Candida albicans and Aspergillus fumigatus (4/4)

Galapagos Genomics NV* (Beligum)

The Flemish Institute for the Promotion of Industrial Scientific-Technological Research and the Netherlands Institute for the Stimulation of Technological Development and Collaboration

€4 (US$3.86)

Technology development grant

For a project to build libraries of specific human gene classes to discover therapeutic targets, and to develop an adenoviral-based knockdown technology applicable to in vitro and in vivo target discovery and validation (6/20)

Icogen Corp.*

National Institute of Allergy and Infectious Diseases

ND

SBIR grant

To fund the first application of Icogen's new high-throughput GPCR activator screening technology (4/23)

Illumina Inc. (ILMN)

National Cancer Institute

$1.2

Phase II research grant

To develop an immunoassay system based on Illumina's BeadArray technology (3/12)

Illumina Inc. (ILMN)

National Institutes of Health

$1

SBIR grant

To further develop the company's Phase II studies in Bead-Array technology for parallel processing of array experiments (5/10)

Indevus Pharmaceuticals Inc. (IDEV; formerly Interneuron Pharmaceuticals Inc., IPIC)

UK's Department of International Development

£16 (US$22.7)

Research grant

To test PRO 2000 and other vaginal microbicides designed to prevent HIV transmission; the grant supports a five-year program involving UK and African research groups (2/19)

Introgen Therapeutics Inc. (INGN)

National Cancer Institute

$0.493

SBTTR grant

To fund collaborative research between Introgen and Elizabeth Grimm, of the University of Texas M.D. Anderson Cancer Center, and to advance preclinical development of INGN 241 (1/22)

Ixion Biotechnology Inc.*

National Institutes of Health

$0.099

SBIR grant

To test a process that could trans-differentiate human bone marrow stem cells and mesenchymal stem cells into insulin producing islets (3/5)

Ixion Biotechnology Inc.*

National Institutes of Health

$0.1

SBIR grant

To test the hypothesis that liver stem cells can transdifferentiate into pancreatic endocrine cells, especially insulin-producing cells (6/21)

Karo Bio USA Inc. (Sweden; SSE:KARO)

Department of the Army

ND

Three-year grant

For drug discovery in prostate cancer (3/12)

Kosan Biosciences Inc. (KOSN)

National Institute of Allergy and Infectious Diseases

$0.23

Phase I SBIR grant

To engineer Escherichia coli strains for improved production of polyketides (3/28)

Kosan Biosciences Inc. (KOSN)

National Institute of Standards and Technology

$2

Advanced Technology Program grant

To support fundamental research in the de novo assembly of polyketide synthases by combinatorial biosynthesis (6/12)

Kosan Biosciences Inc. (KOSN)

National Institutes of Health

$0.1

Phase I SBIR grant

To support its program to generate improved geldanamycin analogues to treat cancer (4/19)

Kosan Biosciences Inc. (KOSN)

National Institutes of Health

$0.1

Phase I SBIR grant

To support its program to generate epothilone analogues by partial chemical synthesis (5/8)

Lexrite Labs Inc.*

National Cancer Institute

$0.5

Phase I SBIR grant

To extend its antibody conjugate technology to develop new drugs capable of permanently binding to a selected tumor antigen on adenocarcinoma cells (4/15)

LifeCell Corp. (LIFC)

Office of Naval Research

$0.824

Three-year grant

To continue funding LifeCell's cell preservation program (2/21)

Mendel Biotechnology Inc.*

National Cancer Institute

ND

SBIR grant

To fund research to discover naturally occurring plant genes that regulate the production of Taxol, a taxoid produced in the cells of yew trees (6/13)

Mendel Biotechnology Inc.*

U.S. Department of Agriculture

ND

SBIR grant

To fund research to discover naturally occurring plant genes that regulate the production of natural rubber (5/21)

Mixture Sciences Inc.*

National Institutes of Health

$0.6

Phase I SBIR grant

To use its technology involving large combinatorial peptide libraries to identify and optimize peptide mimics of HIV-1 epitopes for use in the design of prophylactic vaccines for the treatment of HIV infections (1/17)

Morewood Molecular Sciences Inc.*

National Institutes of Health

ND

Phase I SBIR grant

To support development of its high-throughput enzyme-assaying technology (5/20)

Nonlinear Dynamics Ltd.* (UK)

Department of Trade and Industry

$0.63

Smart Exceptional Development award

To fund a research-based project for the development of Progenera, a bioinformatics data engine with distributed computing technology to offer high-throughput data analysis management and mining solutions (4/18)

Novasite Pharmaceuticals Inc. (subsidiary of Applied Molecular Evolution Inc.; AMEV)

National Institutes of Health

$2.4

Two-year grant

To support the development of anti-obesity drug candidates (4/2)

Novirio Pharmaceuticals Ltd.*

European Commission

€1.9 (US$1.64)

Research grant

To fund a research project titled “Flavitherapeutics“ (1/25)

Ontogen Corp.*

National Institutes of Health

$1.3

Phase II SBIR grant

For the development of enzyme inhibitors to aid in the regulation of blood glucose levels in people with Type II diabetes (1/8)

Oxford BioMedica plc* (UK)

USA Amyotrophic Lateral Sclerosis Association

$0.12

Research grant

To assess a series of five genes as components of a product to address the motor neuron disease market, of which Lou Gehrig's disease is the most common manifestation (6/25)

Panacea Pharmaceuticals Inc.*

National Institute of Aging

ND

Phase I SBIR grant

To support research and development activities aimed at producing therapeutic drugs against the enzyme Human Aspartyl Beta-Hydroxylase (5/21)

Panacos Pharmaceuticals Inc.*

National Institute of Allergy and Infectious Disease

$0.125

Phase I SBIR grant

To support the preclinical development of PA-457, an inhibitor of HIV infection by a mechanism distinct from approved drugs (5/23)

Paradigm Genetics Inc. (PDGM) and LION bioscience AG (Germany; LEON)

National Institute of Standards and Technology

$11.7

Advanced Technology Program grant

To support the development of a target assessment technologies suite, which is intended to increase the number and success rate of validated targets for product development (6/11)

Pharmasset Inc.*

National Institutes of Health

$0.1

Phase I SBTTR grant

To fund research to develop nucleoside analogues cytotoxic only to Epstein-Barr virus thymidine kinase-expressing cells (1/7)

Pharmos Corp. (PARS)

Office of the Chief Scientist of Israel's Ministry of Industry and Trade

$2.8

Development grant

To help fund the development of dexanabinol for traumatic brain injury (6/6)

Phase 2 Discovery Inc.*

National Institute of Neurological Disorders and Stroke

$1

Phase II SBIR grant

To support the development of an early biomarker for predicting clinical outcome in patients with severe head injury (5/2)

Phylos Inc.*

National Institute of Allergy and Infectious Diseases

ND

Phase II SBIR grant

To provide further funding over the next two years to develop a multiplex cytokine array using its Trinectin-binding proteins as capture and detection agents (6/17)

Plexus Vaccine Inc.*

Center for the Commercialization of Advanced Technologies

ND

Department of Defense grant

To provide research and development funding that enables Plexus to acquire proof of concept for vaccine development for a biowarfare target (2/8)

Prana Biotechnology Ltd. (Australia; PRNAF; ASX:PBT)

Australian government

ND

Research grant

To identify new peptides that cause degeneration in the brain (2/4)

ProteoTech Inc.*

National Institute of Aging

$2.78

Research grants

For programs designed to lead to therapeutics for the prevention and treatment of brain amyloid protein deposits present in patients with Alzheimer's disease (2/20)

Psychiatric Genomics Inc.*

National Institute of Child Health and Human Development

$0.1

Phase I SBIR grant

To support research to discover small-molecule nonpeptide agonists of the human secretin receptor for possible use in treating autism (5/29)

Puresyn Inc.*

National Institutes of Health

$0.75

Phase II SBIR grant

To support development of improved methods for purification of adeno-associatedviral vectors at scales suitable for production of gene therapies (6/21)

Q3DM Inc.*

National Institutes of Health

$1.5

Phase II SBIR grant

To further develop Q3DM's high-throughput, high-resolution cellular imaging systems (3/6)

SIGA Technologies Inc. (SIGA)

National Institutes of Health

$0.865

Phase II SBIR grant

To support the company's antibiotic development program at its research and development facility in Corvallis, Ore. (5/29)

SignalGene Inc. (Canada; TSE:SGI)

Genome Canada and Genome Quebec

C$8.1 (US$5.1)

Research grants

SignalGene received the funding for a program focused on three disorders related to steroid hormones, namely osteoporosis, breast cancer and ovarian cancer (4/3)

Southwest Foundation for Biomedical Research*

National Institutes of Health

$6.2

Five-year grant

For advancing the medical community's understanding of antiprogestins; the foundation's senior scientist, Pemmaraju Rao, received the grant (4/16)

The Biotechnology Institute*

Wyeth Inc.

$1

Challenge grant

To support biotechnology education (6/13)

TransMolecular Inc.*

National Institutes of Health

$0.76

Phase II SBIR grant

To discover and develop pharmaceutical alternatives over the next two years for treating neuropathic pain (4/18)

UK BioBank*

Wellcome Trust, UK Medical Research Council and the UK Department of Health

£45 (US$65.6)

Research grant

To collect DNA samples and health and lifestyle information from 500,000 volunteers; the samples will be held in public ownership for public benefit (4/29)

Viragen Ltd. (Scotland; division of Viragen Inc.; AMEX:VRA)

Scottish government

$0.65

Development grant

For the development of avian transgenic technology in collaboration with the Roslin Institute(5/16)

Viscum AG* (Germany)

German Research Ministry

€2.55 (US$2.2)

Four-year research grant

For the development of cancer therapies based on fusion toxins (3/27***)

Wyeth Vaccines (unit of Wyeth Pharmaceuticals; NYSE:WYE)

National Institute of Allergy and Infectious Diseases

$22.8

Research grant

For five years to expand research on a vaccine shown to prevent an AIDS-like disease in monkeys (5/17)

Xenerex Biosciences (subsidiary of Avanir Pharmaceuticals Inc.; AMEX:AVN)

Center for Commercialization of Advanced Technology

$0.075

Development grant

To fund the initial development of a treatment that is intended to reduce the potentially damaging effects of exposure to anthrax toxins in humans (6/19)

Xenon Genetics Research Inc.* (Canada)

Genome Canada and Genome Quebec

C$11 (US$6.9)

Research grant

To support two projects in genomics-based drug discovery (4/3)

XenoPort Inc.*

National Institutes of Health

$0.145

Phase I SBIR grant

To support development of new methods for identifying transcytosis pathways to be used in improving the oral absorption of certain drugs (4/10)

TOTAL: $194.447M

Notes:

This chart does not include grants that are tied to agreements between biotech companies and non-profit institutions.

* Indicates a privately held company or institution.

** Unless otherwise indicated, symbols listed are on the Nasdaq market.

*** Denotes the date the item ran in BioWorld International.

ND = not disclosed; SBIR = Small Business Innovation Research; SBTTR = Small Business Technology Transfer Research

AMEX = American Stock Exchange; ASX = Australian Stock Exchange; NYSE = New York Stock Exchange; SSE = Stockholm Stock Exchange; TSE = Toronto Stock Exchange

No Comments